MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

TLRY

6.95

+0.43%↑

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

TLRY

6.95

+0.43%↑

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

TLRY

6.95

+0.43%↑

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

TLRY

6.95

+0.43%↑

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

TLRY

6.95

+0.43%↑

Home・Elenco Azioni・Fate Therapeutics Inc

Fate Therapeutics Inc

Chiusa

SettoreSettore sanitario

1.29 -3.73

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

1.25

Massimo

1.35

Metriche Chiave
By Trading Economics
Entrata	-124K -32M
Vendite	-372K 1.4M
EPS	-0.27
Margine di Profitto	-2,364.792
Dipendenti	161
EBITDA	-13M -42M

Raccomandazioni
By TipRanks
Raccomandazioni	Neutrale
Previsioni per 12 mesi	+52.67% upside

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-36M 138M
Apertura precedente	5.02
Chiusura precedente	1.29

Notizie sul Sentiment di mercato

By Acuity

15%

85%

22 / 348 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

0.9101 / 1.14 Supporto e resistenza

Fate Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

14 apr 2026, 23:36 UTC

Acquisizioni, Fusioni, Takeovers

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion -- Update

14 apr 2026, 23:24 UTC

Azioni calde

Stocks to Watch: Gloo, Broadcom, GitLab

14 apr 2026, 22:42 UTC

Acquisizioni, Fusioni, Takeovers

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion

14 apr 2026, 21:32 UTC

I principali Market Mover

GitLab Shares Rise on Expanded Google Cloud Collaboration

14 apr 2026, 23:54 UTC

Discorsi di Mercato

Nikkei May Rise as Fears About Energy Shortage Ease -- Market Talk

14 apr 2026, 23:34 UTC

Discorsi di Mercato

Gold Edges Lower on Possible Technical Correction -- Market Talk

14 apr 2026, 22:54 UTC

Utili

BRP: Amendment Mainly Leads to 25% Tariff on Total Value of Imported Snowmobiles and Majority of ORV Models, Replacing Previous 50% Tariff on Applicable Metal Content Only >DOO.T

14 apr 2026, 22:54 UTC

Utili

BRP: Suspending Guidance Following Amendment of Section 232 Tariffs on Steel, Aluminum and Copper Imports Into U.S., Which Came Into Effect on April 6 >DOO.T

14 apr 2026, 22:54 UTC

Utili

BRP: Currently Estimates Potential Incremental Tariff Cost Related to This Amendment in Excess of $500M for Remainder of Yr >DOO.T

14 apr 2026, 22:54 UTC

Utili

BRP: Suspends FY27 Guidance Due to Changes to U.S. Tariff Environment

14 apr 2026, 22:17 UTC

Acquisizioni, Fusioni, Takeovers

Yancoal Australia: Targets Deal Completion Toward End of 3Q

14 apr 2026, 22:17 UTC

Acquisizioni, Fusioni, Takeovers

Yancoal Australia: Acquisition Diversifies Portfolio; Met Coal Share to Rise to 22%

14 apr 2026, 22:17 UTC

Acquisizioni, Fusioni, Takeovers

Yancoal Australia: Asset 'Strong Strategic Fit'; to Positively Add Production, Cash Flow

14 apr 2026, 22:16 UTC

Acquisizioni, Fusioni, Takeovers

Yancoal Australia: Intends to Fund Acquisition With Cash, 5-Year Loan Facility

14 apr 2026, 22:15 UTC

Acquisizioni, Fusioni, Takeovers

Yancoal Australia: Contingent Consideration Linked to Average Annual Prices For 5 Years

14 apr 2026, 22:14 UTC

Acquisizioni, Fusioni, Takeovers

Yancoal Australia: Deal Includes Contingent Cash Consideration Up to $550 Million

14 apr 2026, 22:13 UTC

Acquisizioni, Fusioni, Takeovers

Yancoal Australia: Deal Includes $1.85 Billion Upfront Consideration

14 apr 2026, 22:12 UTC

Acquisizioni, Fusioni, Takeovers

Yancoal Australia: To Buy Kestrel Stake From EMR Capital, Adaro Capital

14 apr 2026, 22:12 UTC

Acquisizioni, Fusioni, Takeovers

Yancoal Australia: To Buy Kestrel Stake For Up to $2.4 Billion

14 apr 2026, 22:10 UTC

Acquisizioni, Fusioni, Takeovers

Yancoal Australia: to Acquire 80% Interest in Kestrel Coal Mine

14 apr 2026, 20:50 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Basic Materials Roundup: Market Talk

14 apr 2026, 20:33 UTC

Acquisizioni, Fusioni, Takeovers

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

14 apr 2026, 20:32 UTC

Azioni calde

Stocks to Watch: JPMorgan, American Airlines, LVMH, BlackRock -- WSJ

14 apr 2026, 19:59 UTC

Acquisizioni, Fusioni, Takeovers

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

14 apr 2026, 19:38 UTC

Utili

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14 apr 2026, 19:27 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Extend Losing Streak -- Market Talk

14 apr 2026, 19:21 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Oil Futures Retreat on Hopes for U.S.-Iran Peace Talks -- Market Talk

14 apr 2026, 19:09 UTC

Acquisizioni, Fusioni, Takeovers

Apple and Amazon Partner on Satellite Deal. Why It Makes Sense. -- Barrons.com

14 apr 2026, 18:30 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

14 apr 2026, 18:30 UTC

Discorsi di Mercato

Treasury Yields, Dollar Fall as Markets Price Higher Odds of Fed Cuts -- Market Talk

Confronto tra pari

Modifica del prezzo

Fate Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

52.67% in crescita

Previsioni per 12 mesi

Media 2 USD 52.67%

Alto 2 USD

Basso 2 USD

Basato su 3 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Fate Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

3 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 3 che hanno fornito valutazioni azionarie a Fate Therapeutics Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

0.9101 / 1.14Supporto e resistenza

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

22 / 348 Classifica in Settore sanitario

Notizie finanziarie

Chi Siamo Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.